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Background: A combination treatment of interferon and ribavirin is the standard and the commonly used
treatment for chronic hepatitis C (CHC). Developing noninvasive tests like serum indicators that can predict
treatment outcome at an early stage of therapy is beneficial for individualized treatment and management of CHC.
A glyco-indicator based on the glyco-alteration of serum α1-acid glycoprotein, LecT-Hepa, was discovered by
glycomics technologies as a robust indicator of liver fibrosis. Here, we investigated the clinical utility of LecT-Hepa
for evaluation of treatment outcome.
Results: Firstly, ninety-seven patients with CHC were used for comparison of LecT-Hepa in serum and plasma. We
found no significant difference in the concentrations of LecT-Hepa in serum and plasma. And then, 213 serum
specimens from 45 patients who received 48 weeks of treatment with interferon and ribavirin were followed up for
96 weeks, and were used for evaluation of the role of LecT-Hepa. We found that LecT-Hepa might reflect the
change in fibrosis regression during the treatment process. Moreover, the change of LecT-Hepa at the first 12 weeks
of treatment could already predict the antiviral treatment response, which was more superior to FIB-4 index and
aspartate aminotransferase-to-platelet ratio index (APRI) in this study.
Conclusions: These results provide a new perspective that serum glycoprotein could be used as a joint diagnosis
indicator for estimation treatment outcome of viral hepatitis at earlier stage of therapy.
Keywords: Glycoprotein, LecT-Hepa, Non-invasive, Treatment outcome, CHCIntroduction
Chronic hepatitis C virus (HCV) infection is a highly
prevalent public health concern and one of the leading
causes of cirrhosis, hepatocellular carcinoma, and liver
failure [1]. An estimated 150 million people worldwide
are chronically infected with HCV, and >350,000 people
die from hepatitis-C-related liver diseases every year [2].
The standard treatment widely used for chronic hepatitis
C (CHC) is a combination of peginterferon and ribavirin* Correspondence: junqiniu@aliyun.com; yanzhang2006@sjtu.edu.cn
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unless otherwise stated.[3,4]. The indication of successful therapy is the attain-
ment of sustained virological response (SVR), which is
defined as undetectable serum HCV RNA 24 weeks after
treatment cessation [5]. With the current standard treat-
ment, patients with chronic HCV infection show an
SVR rate of ~55% [6,7]. This means that there is a large
population of patients with treatment outcomes of no
response, virological breakthrough, or relapse. Early predic-
tion of the outcome during or after treatment is expected
to provide additional information for individualizing treat-
ment, and thus improves the cure rates for patients with
chronic HCV infection.
One of the most important histological outcomes of
interferon (IFN) therapy is the change in degree of fibro-
sis. Many studies have clearly shown that IFN therapy
results in significant regression of fibrosis in patients whois is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,




specimens (n = 97)
CHC patients treated
with IFN and achieved
RVR (n = 45)
Age (year) 52.30 ± 8.20 52.64 ± 7.49
Gender (male/female) 55/42 30/15
TBIL (μmol/L) 16.90 ± 7.40 /
DBIL (μmol/L) 7.47 ± 3.14 /
ALP (U/L) 88.41 ± 31.01 /
GGT (U/L) 79.79 ± 91.21 /
ALT (U/L) 57.88 ± 50.87 119.71 ± 110.95
AST (U/L) 45.50 ± 32.49 87.70 ± 82.70
PLT (×109/L) 189.07 ± 66.50 166.60 ± 83.20
FibroScan 9.44 ± 10.22 15.16 ± 7.63
MAL/DSA Serum: 10.01 ± 1.94 9.29 ± 2.39
Plasma: 10.35 ± 2.30
AOL/DSA Serum: 3.02 ± 3.43 6.34 ± 7.33
Plasma: 3.57 ± 4.78
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http://www.clinicalproteomicsjournal.com/content/11/1/44attain SVR [8-10]. Thus, continuous monitoring of the
degree of liver fibrosis should be beneficial for early esti-
mation of the therapeutic efficacy and long-term follow-
up of patients, which provides clues for the prognosis and
management of CHC. It is evident that liver biopsy is con-
sidered as the gold standard for fibrosis staging [11]. This
procedure has several disadvantages including invasive-
ness, potential complications, and sampling errors, which
often limit its application, for example, frequent moni-
toring of the degree of fibrosis [12-14]. The development
of noninvasive methods to complement liver biopsy is
urgently needed. From this point of view, a variety of non-
invasive methods has been developed, including physical
techniques such as FibroScan [15] and serological tests
such as FibroTest, Hepascore, enhanced liver fibrosis
(ELF) index, platelets, APRI, and FIB-4 index [16-19].
FibroScan is recognized as a superior test for evaluation of
fibrosis compared with biochemical markers [20]. It is
restricted by the cost and the operator’s experience and
patient’s body mass index (BMI) [21]. Many serological
methods are also moderately useful for identifying signi-
ficant fibrosis or cirrhosis in patients with chronic HCV
infection. However, there are few serological tests reported
to meet the above medical need.
Our previous study using glycomics technologies have
developed and revealed a new fibrosis test named LecT-
Hepa, which measures a glycobiomarker serum α1-acid
glycoprotein (AGP) with fibrosis-related glyco-alterations
performed well in estimating liver fibrosis [22]. It is cor-
related well with the fibrosis stage determined by liver bi-
opsy [22-24] and FibroScan [25], either in a single-center
[22,23] or a multicenter study [24]. In the present study,
continuous use of LecT-Hepa as an indicator of liver fi-
brosis during 48 weeks therapy with IFN and ribavirin led
us to predict the outcome within the treatment period.
We found that the change of LecT-Hepa just at the first
12 weeks of therapy could already distinguish CHC
patients’ attainment of SVR.
Results
Evaluation of the level of LecT-Hepa in serum and plasma
specimens
LecT-Hepa has been shown as a reliable method for the
evaluation of liver fibrosis [22,24,25]. However, previous
studies were all conducted using serum specimens. To
broaden the clinical application of LecT-Hepa, we com-
pared the concentration of LecT-Hepa in serum and
plasma prepared simultaneously from the same individ-
uals. A total of 97 patients with confirmed CHC were
included for this comparison (Table 1). As shown in
Figure 1, we observed a significant linear correlation
between the level of LecT-Hepa in serum and that in
plasma (R2 = 0.6766, p < 0.0001), with most of the pa-
tients (89 of 97) within the 95% confidence intervals ofthe correlation. In addition, according to the best linear
curve with its correlation coefficient (y = 0.9653x), the
concentrations of LecT-Hepa in serum and plasma were
almost the same. These data suggest that the serum and
plasma specimens could both be used for clinical detec-
tion of LecT-Hepa.
Baseline characteristics of 45 patients achieved rapid
virological response (RVR)
A total of 45 CHC patients who had achieved RVR during
IFN therapy and undergone 2 years of follow-up were
used for the evaluation of the role of LecT-Hepa during
hepatitis C treatment and follow-up. The mean age of the
45 patients was 52.64 ± 7.49 years, and 30 (66.7%) of them
were men (Table 1). To investigate the relation between
the level of LecT-Hepa and fibrosis, these patients were
divided into three groups based on the degrees of severity
of liver fibrosis assessed by FibroScan. According to the
study by Berzigotti et al. [26], 18 (40.0%) patients with
FibroScan value <12 kPa and 13 (28.9%) with FibroScan
value ≥18 kPa were considered as non-cirrhosis (non-
LC) and cirrhosis (LC), respectively. Other patients with
FibroScan values of 12–18 kPa were indeterminate. We
also assessed the degree of fibrosis using color Doppler
ultrasound. The results were highly consistent with the
assessment by FibroScan (Table 2). In addition, the baseline
characteristics of these patients are also summarized in
Table 2. For the routine clinical indicators, platelet count
(PLT) showed the most significant differences (p = 0.004
for non-LC vs. indeterminate, and p = 0.001 for non-LC vs.
LC respectively, Student’s t test), while other indicators
























Figure 1 Correlation of concentrations of LecT-Hepa in serum and plasma specimens prepared simultaneously from the same individuals.
The linear regression analysis was performed in 97 patients with confirmed CHC. The best-fit linear comparison with its correlation coefficient was
calculated in Excel 2007 (Microsoft). The dotted line shows the 95% confidence intervals of the correlation.
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for the new indicator, both MAL/DSA and AOL/DSA
always showed significant differences among the three
groups. In addition, the univariate analysis revealed that





Age (year) 49.28 ± 5.74 55.00 ± 8.64
Gender (male/female) 11/7 12/2
BMI 23.15 ± 3.01 22.21 ± 3.01
AST (U/L) 54.46 ± 45.25 110.05 ± 100.31
ALT (U/L) 87.68 ± 88.70 137.44 ± 111.08
PLT (×109/L) 218.22 ± 98.68 140.64 ± 46.25
MAL/DSA 11.02 ± 1.44 8.82 ± 2.22
AOL/DSA 1.94 ± 1.08 6.42 ± 4.14
Color Doppler ultrasound assessment*
1 87.5% (14/16) 50.0% (6/12)
2 12.5% (2/16) 16.7% (2/12)
3 0.0% (0/16) 33.3% (4/12)
4 0.0% (0/16) 0.0% (0/12)
*2 patients in each group were not measured by color Doppler ultrasound.non-LC and LC groups, whereas the indeterminate and
LC groups showed no difference. We observed a significant
decrease in the level of MAL/DSA (p = 2.68E-06 vs. non-
LC) and an increased level of AOL/DSA (p = 0.004 vs.










54.77 ± 7.06 p = 0.032 p = 0.940 p = 0.024
7/6 p = 0.235 p = 0.103 p = 0.727
23.62 ± 3.19 p = 0.388 p = 0.248 p = 0.677
109.66 ± 92.28 p = 0.044 p = 0.992 p = 0.035
144.97 ± 134.27 p = −.169 p = 0.875 p = 0.163
123.07 ± 49.34 p = 0.011 p = 0.349 p = 0.003
7.41 ± 2.03 p = 0.002 p = 0.100 p = 2.68E-06
12.35 ± 10.41 p = 0.001 p = 0.059 p = 0.004
0.0% (0/11) p = 0.044 p = 0.014 p = 5.98E-06
45.4% (5/11) p = 1.000 p = 0.193 p = 0.084
36.4% (4/11) p = 0.024 p = 1.000 p = 0.019
18.2% (2/11) p = 1.000 p = 0.217 p = 0.157
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http://www.clinicalproteomicsjournal.com/content/11/1/44new indicator LecT-Hepa may be superior to the routine
clinical indicators for the evaluation of fibrosis in this
cohort.
Evaluation of LecT-Hepa, FIB-4, and APRI for estimating
progression of liver fibrosis during IFN treatment of
HCV-infected patients
In HCV-infected patients, evaluation of the progression
of fibrosis is an important indicator of antiviral therapy
[17]. However, only a few serum markers have been re-
ported for predicting fibrosis progression and regression
during treatment. Here, we investigated the relation
between LecT-Hepa and fibrosis progression. First, we
performed a correlation analysis of LecT-Hepa against the
fibrosis levels measured by FibroScan at different times
during treatment. As shown in Figure 2, we observed
a significant linear correlation between the level of
LecT-Hepa and FibroScan before (0 weeks R2 = 0.6790,
p < 0.0001) and after (24 weeks, R2 = 0.6387, p = 0.0077
and 48 weeks, R2 = 0.7311, p = 0.0006) treatment. This
suggests that change in LecT-Hepa reflects a change in
FibroScan during IFN treatment. Then, we performed a
trend analysis of LecT-Hepa, FIB-4, and APRI during
48 weeks of IFN therapy. As shown in Figure 3A, all
CHC patients in the non-LC group had LecT-Hepa
values <0, while the mean level of LecT-Hepa in patients
with LC was >0. A gradually increasing trend of LecT-
Hepa from the non-LC to the LC group was observed.
The difference in LecT-Hepa between the three groups
was significant at different times during treatment
(p < 0.0001 for 0, 4, 12 and 24 weeks). The level of FIB-4
was also higher in the LC than in the non-LC group, and
the mean level of FIB-4 in the LC group was higher than
the reference cutoff value of 3.45 for cirrhosis [27]. How-
ever, this trend was not obvious and regular in all pa-
tients. In contrast, APRI showed lesser changes between
the non-LC and LC groups. These results indicated that
LecT-Hepa was effective for evaluation of the progression
of fibrosis, at least in this cohort.
To investigate the change in LecT-Hepa during the
48-week course of IFN therapy in detail, we analyzed the




































Figure 2 Correlation of concentrations of LecT-Hepa and FibroScan v
the treatment process.48 weeks of therapy in 45 CHC patients (Additional file 1:
Figure S1 and Table 3). The mean level of LecT-Hepa was
increased from −4.69 to −3.25 in the LC group (p = 0.076,
paired t test) during the early phase of therapy (0–4
weeks), followed by a small but meaningful reduction
after viral elimination (from 4 to 12, 24, and 48 weeks)
(the mean value from −3.25 to −3.24, −4.19 and −7.31,
p = 0.029 from 4 to 24 weeks, p = 0.026 from 12 to
24 weeks). For the other two indices, APRI showed a dra-
matic decrease during the early stage of IFN treatment
(0–4 weeks) (p = 0.0009, paired t test), followed by a more
stable trend (mean value from 0.81 to 0.83, 0.78 and 0.76,
p = 0.275, one-way ANOVA), whereas FIB-4 showed no
clear regular changes during IFN treatment. Combined
with the significant correlation of LecT-Hepa and FibroS-
can, we suggest that the change in LecT-Hepa is superior
to FIB-4 and APRI for describing the changes in fibrosis
during IFN treatment in this cohort.
Evaluation of the role of LecT-Hepa in prognosis of
patients with HCV
To evaluate the relationship between changes in LecT-
Hepa and prognosis of CHC patients, we compared the
levels of LecT-Hepa, FIB-4, and APRI in 45 patients who
attained RVR with different treatment outcomes (SVR or
non-SVR). Patients who attained RVR had undetectable
HCV RNA after 4 weeks of therapy. We compared the
clinical characteristics including the serum index between
SVR and non-SVR groups (Table 4). For the serum indi-
cators LecT-Hepa, FIB-4, and APRI, we calculated the R-
value given as the sum of the changes from 4 to 12 weeks
(R = 12–4 weeks) during IFN treatment, which showed
the variation after viral elimination and reflected the early
outcome of treatment. Besides the effect of serum HCV
RNA level on treatment outcome, it is worth noting that
at 12 weeks of therapy, only R value of LecT-Hepa showed
a significant difference (p = 0.0031, Mann–Whitney U test)
between SVR and non-SVR groups, while those of the
other two indicators were not (p = 0.5545 for FIB-4 and
p = 0.7626 for APRI) (Figure 4A). Those results suggest
that the change in LecT-Hepa at the first 12 weeks of
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Figure 3 Trend analysis of the levels of LecT-Hepa, FIB-4, and APRI during 48 weeks of IFN treatment. Forty-five patients with CHC who
achieved RVR were classified into non-LC (<12 kPa, n = 18), indeterminate (12–18 kPa, n = 14), and LC (≥18 kPa, n = 13) groups according to the
degrees of severity of liver fibrosis assessed by FibroScan. Trend analysis of the levels of LecT-Hepa (A), FIB-4 (B), and APRI (C) during the treatment
process in these three groups was performed.
Table 3 Levels of LecT-Hepa, FIB-4 and APRI in45 CHC patients during 48 weeks course of IFN therapy
Weeks 0 4 12 24 48
LecT-Hepa
Non-LC (n = 18) −9.22 ± 3.77 −9.09 ± 4.66 −8.72 ± 5.66 −8.71 ± 4.69 −8.98 ± 4.88
Indeterminate (n = 14) −2.10 ± 4.63 −2.14 ± 5.02 −2.12 ± 4.72 −3.47 ± 5.13 −4.40 ± 5.01
LC (n = 13) 0.83 ± 5.06 2.82 ± 5.60 2.38 ± 5.32 1.29 ± 4.39 −0.17
Total (n = 45) −4.69 ± 6.11 −3.25 ± 7.01 −3.24 ± 6.97 −4.19 ± 6.21 −7.31 ± 5.35
FIB-4
Non-LC (n = 18) 1.63 ± 1.06 1.72 ± 0.70 2.03 ± 0.94 1.87 ± 1.03 1.81 ± 0.68
Indeterminate (n = 14) 4.17 ± 3.11 2.79 ± 2.17 3.33 ± 2.49 2.91 ± 1.61 2.84 ± 0.91
LC (n = 13) 4.57 ± 2.71 3.80 ± 1.95 4.35 ± 1.91 3.94 ± 1.53 4.55
Total (n = 45) 3.27 ± 2.68 2.70 ± 1.85 3.15 ± 2.04 2.79 ± 1.60 2.22 ± 1.01
APRI
Non-LC (n = 18) 0.96 ± 1.11 0.54 ± 0.27 0.58 ± 0.36 0.51 ± 0.29 0.66 ± 0.76
Indeterminate (n = 14) 2.44 ± 2.18 0.70 ± 0.32 0.76 ± 0.37 0.82 ± 0.56 0.89 ± 0.48
LC (n = 13) 2.92 ± 3.15 1.26 ± 0.61 1.19 ± 0.45 1.10 ± 0.46 1.44
Total (n = 45) 1.98 ± 2.31 0.81 ± 0.52 0.83 ± 0.46 0.78 ± 0.49 0.76 ± 0.69
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Age (year) 52.13 ± 7.86 53.78 ± 7.20 p = 0.4530
Gender p = 0.7020
Male 14 12
Female 9 6
BMI 23.22 ± 2.98 22.27 ± 2.95 p = 0.3510
ALT (U/L)2 156.59 ± 134.65 80.74 ± 67.90 p = 0.0659
AST (U/L)2 104.59 ± 97.74 65.27 ± 59.63 p = 0.1180
PLT (×109/L)2 138.30 ± 57.34 205.94 ± 102.76 p = 0.0551
AFP 2 2.99 ± 1.23 4.68 ± 2.96 p = 0.0841
HCV RNA
(×106 eq/mL)2
1.15 ± 1.60 8.78 ± 9.92 p = 0.0051








R of LecT-Hepa −0.60 ± 1.48 0.79 ± 1.54 p = 0.0031
R of FIB4 0.38 ± 2.00 0.62 ± 1.76 p = 0.5545
R of APRI 0.01 ± 0.60 0.04 ± 0.28 p = 0.7626
1)4 of 45 patients were lost to follow-up.
2)Clinical information was the baseline (0 weeks) information.
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http://www.clinicalproteomicsjournal.com/content/11/1/44outcome than FIB-4 and APRI were. In addition, from
this preliminary result, we found that R value of LecT-
Hepa were higher in patients who have not attained SVR.
Furthermore, to evaluate the overall diagnostic perfor-
mances and attempt to establish clinically useful cut-off
levels of these serum indices, we constructed receiver-
operating characteristic (ROC) curves for R-values of
LecT-Hepa, FIB-4, and APRI. As shown in Figure 4B,
the area under the curve (AUC) (95% CI) of LecT-Hepa
for distinguishing between SVR and non-SVR patients
(0.773, 0.615–0.889) was superior to FIB-4 (0.556, 0.392–
0.720) and APRI (0.471, 0.314–0.633), and the difference
were significant between LecT-Hepa and the other two
indicators (p = 0.043 vs. FIB-4 and p = 0.011 vs. APRI).
Based on Youden’s index from the ROC curve, the opti-
mal cut-off value of LecT-Hepa was −0.0934, with sensi-
tivity of 83.33%, specificity of 60.87%, positive predictive
value (PPV) of 62.5%, and negative predictive value (NPV)
of 82.4%. These results implied that the change in the
serum level of glycoprotein LecT-Hepa could predict the
antiviral treatment response more quickly than FIB-4 and
APRI, even at the first 12 weeks of therapy, which may
provide more precise information for treatment protocols
of CHC.Discussion
For patients with CHC, the traditional therapy is a com-
bination of IFN and ribavirin. Recently, with the develop-
ment of many other drugs targeting viral or host factors,
and the approval of two direct-acting antiviral agents
[28,29], the question of who should be treated and with
what regimen has become increasingly complex to address
and needs more careful consideration [3]. Liver biopsy
is considered as the gold standard for fibrosis staging.
However, it cannot be used for continuously monitoring
the progression of hepatitis because of its invasiveness
and lack of accuracy. Thus, developing noninvasive tests
like serum indictors that could continuously monitor
the histological progression of hepatitis during therapy
is beneficial for providing information for physicians
and optimization of treatment. At present, a few bio-
markers have been reported to predict the response to
IFN-based regimens before the start of antiviral therapy
[30-32]. For example, a recent study has suggested that
patients with a favorable interleukin-28 (IL28B) genotype
can receive peginterferon and ribavirin first, with the
approved triple therapy subsequently if the initial treat-
ment fails [33]. In addition, the pretreatment interferon-
gamma-inducible protein-10 (IP-10) levels in plasma can
predict RVR and SVR in patients infected with HCV
genotype 1, and thus may be helpful in decision making
regarding pharmaceutical intervention [34]. However, it
should be stressed that there are few biomarkers that can
monitor the progression of hepatitis during therapy. Thus,
in this study, we focused on the potential predictive value
of serum LecT-Hepa level during treatment with IFN and
ribavirin. We analyzed the clinical information, including
serum levels of LecT-Hepa, FIB4, and APRI. We clearly
showed changes in serum level of LecT-Hepa during
IFN treatment. We are particularly interested in the small
reduction in LecT-Hepa after viral elimination (from 4 to
12 and 24 weeks) because at that time fibrosis began to
ease [35,36]. Based on the significant correlation of LecT-
Hepa and FibroScan, we speculate that the change in
LecT-Hepa may reflect the changes in fibrosis during IFN
treatment (Figures 2 and 3). We only used RVR patients
in this study; all of whom had a ≥2 log10 decrease in HCV
RNA level by 4 weeks of therapy. SVR patients main-
tained a low or undetectable HCV RNA level during
and after therapy. However, non-SVR patients showed
virological breakthrough or relapse during or after therapy
(Additional file 2: Figure S2). Serum levels of ALT and
AST for SVR and non-SVR patients showed a similar ten-
dency, with a dramatic decrease at 0–4 weeks, followed by
a more stable trend. The HCV RNA quantitation became
to decrease and the liver function returned to normal is
the clinical indicators to determine the treatment out-
come. During this process, LecT-Hepa showed a decrease































































Se (%) 83.33 83.33 94.44
Sp (%) 60.87 43.48 30.43
PPV (%) 62.5 53.6 51.5









Figure 4 Evaluation of roles of R-value LecT-Hepa, FIB-4, and APRI in predicting treatment outcome of HCV. (A) Serum levels of LecT-Hepa,
FIB-4, and APRI from 4 to 12 weeks (R = 12 – 4 weeks) were calculated in SVR (n = 23) and non-SVR (n = 18) patients who achieved RVR during the
48-week course of IFN therapy and underwent a 2-year period of follow-up (4 of the 45 patients were lost to follow-up). Mean values are indicated by
a horizontal line and p values were calculated by the Mann–Whitney U test. (B) ROC curves of LecT-Hepa, FIB-4, and APRI for distinguishing patients
with SVR from non-SVR. The cut-off values were based on the Youden’s index from the ROC curve. Se, sensitivity; Sp, specificity.
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(12–24 weeks) for non-SVR patients (Additional file 2:
Figure S2). Our data also showed that the change in LecT-
Hepa was well correlated with the treatment outcome of
CHC (p = 0.0031). If patients had an increased R value in
LecT-Hepa (R = 12–4 weeks), they were more likely to
experience relapse and become non-SVR (Figure 4).
Currently, the mechanism of relapse is not fully under-
stood but several factors have been reported as risk factors
for relapse and response [37], such as viral genotype 1
[38], high viral load [39], metabolic factors [40], shorter
treatment with inadequate doses of ribavirin, and the
degree of liver fibrosis and cirrhosis [41]. Previous reports
have suggested that the index LecT-Hepa is one of the
best candidates for glyco-indicators in liver fibrosis.
LecT-Hepa count is based on the glyco-alternation in
serum AGP. AGP is mainly synthesized in the liver and
its glycosylation has a profound effect on collagen fibrilformation [42,43]. Goodman and Marcellin et al. have
reported that the degree of liver fibrosis is characterized
by a linear increase in fibrillar collagen, which was more
resistant to enzymatic degradation in their studies [44,45].
Thus, we speculate that LecT-Hepa level shows a linear
correlation with the degree of fibrosis. Now, we under-
stand the relation between LecT-Hepa level and treatment
outcome. If the R value (12–4 weeks) is larger, it indicates
that the degree of fibrosis at 12 weeks is more severe than
at 4 weeks. That means that after treatment, liver fibrosis
is not relieved and may become more severe. In other
words, the treatment is not effective in these patients, and
they will likely not attain an SVR. In addition, because
the coagulation process did not affect glycosylation of
AGP, we found that the level of LecT-Hepa showed no
difference in serum and plasma. We also compared the
LecT-Hepa levels in patients with HCV genotype 1a and 2b
(Additional file 3: Figure S3). Those results showed that
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HCV genotype, and the change in LecT-Hepa level indeed
reflected the therapeutic efficacy.
To the best of our knowledge, this is the first study to
investigate the noninvasive serum glyco-marker as a pre-
dictive factor for prognosis of CHC patients undergoing
treatment. The prognostic value of serum LecT-Hepa level
is superior to that of other biochemical markers such as
FIB-4 and APRI just at the first 12 weeks of therapy. In
addition, because the level of LecT-Hepa is positively cor-
related with the degree of fibrosis, it may be used for liver
function monitoring at optimal intervals and for the pre-
diction of the treatment outcome of new antifibrotic drugs.
Conclusions
In summary, this study was a trial for the estimation of
therapeutic efficacy in patients with CHC using serum
glycoproteins. It is an extension of previous study which
has found LecT-Hepa as a good predictor of fibrosis using
glycomics technologies. Our study revealed that the change
in serum level of LecT-Hepa after viral elimination may
serve as an early predictor of antiviral treatment response
in CHC patients treated with IFN and ribavirin, and may
provide additional information for individualizing treat-
ment. This study provides evidence for the clinical value of
serum glycomics and gives a new perspective that the




A total of 142 patients with a positive anti-HCV antibody
and HCV viral load were enrolled from the Department
of Hepatology, First Hospital of Jilin University. Patients
were enrolled after August 2010 and followed up for at
least 48 weeks. Inclusion criteria were (1): diagnosis with
CHC; and (2) HCV RNA was positive as determined
by the COBAS TaqMan HCV test (Roche Diagnostics,
Branchburg, NJ, USA). Exclusion criteria were: (1) co-
infection with another hepatitis virus or HIV; (2) exces-
sive alcohol intake; (3) hepatocellular carcinoma or its
history; and (4) decompensated liver cirrhosis.
This retrospective cohort study was divided into two
parts: One part contained 97 patients with sera and plasma
collected simultaneously. The other part included 213 se-
rum specimens from the remaining 45 patients who
received 48 weeks treatment with IFN and ribavirin,
and were followed up for 96 weeks. All of the 45 patients
achieved an RVR with ≥2 log10 decrease in HCV RNA
level by 4 weeks of therapy. This study was in accordance
with the ethical guidelines of the 1975 Declaration of
Helsinki and was approved by the Ethical Committee of
the First Hospital, Jilin University. Each participant gave
written informed consent.Detection and quantification of HCV RNA
The concentration of HCV RNA in serum was deter-
mined by reverse transcriptase polymerase chain reaction
using the COBAS TaqMan HCV assay (Roche Diagnos-
tics). Serum was collected at different time points during
therapy and follow-up (0, 4, 12, 24, 48, 60, 72, 96, and
144 weeks). According to the viral kinetic response and
treatment outcome, 45 patients were judged as SVR with
undetectable HCV RNA 24 weeks after therapy was
complete, or as non-SVR.
Clinical and biological data
The basic anthropometric parameters, such as age and
sex of the patients were recorded. Serum and plasma
samples were collected and stored at −80°C until analysis.
The serum biochemical parameters, including concen-
trations of total bilirubin (TBIL), direct bilirubin (DBIL),
alkaline phosphatase (ALP), γ-glutamyltransferase (GGT),
ALT, aspartate aminotransferase (AST) and PLT were as-
sessed by the medical laboratory of the First Hospital of
Jilin University. The APRI and FIB-4 index were calcu-
lated according to published formulas [46,47].
Liver stiffness measurement
Liver stiffness was measured by transient elastography
using FibroScan (EchoSens, Paris, France). The measure-
ment depth was between 25 and 65 mm. For each patient,
10 validated measurements were performed. The success
rate was calculated as the number of validated measure-
ments divided by the total number of measurements. The
results were expressed in kilopascals. The median value
was considered representative of the elastic modulus of the
liver. Only procedures with 10 validated measurements
and a success rate of at least 60% were considered reliable.
Automatic acquisition of quantitative glyco-alteration of
AGP (LecT-Hepa)
The detailed procedure for LecT-Hepa has been described
previously [22,25]. Each individual serum or plasma
sample (5 μL) was diluted and heated at 95°C for 20 min
before enrichment of AGP. The AGP in the sample was
enriched by immunoprecipitation with a biotinylated anti-
AGP antibody using an automated protein purification
system (ED-01; GP BioSciences, Tokyo, Japan). Finally,
fibrosis-specific glyco-alteration of the enriched AGPs was
determined by lectin-antibody sandwich immunoassays
with a combination of three lectins (Datura stramo-
nium agglutinin (DSA), Maackia amurensis leukoaggluti-
nin (MAL), and Aspergillus oryzae lectin (AOL)) [23] using
an automated chemiluminescence enzyme immunoassay
system (HISCL-2000i; Sysmex, Kobe, Japan). The criterion
formula of LecT-Hepa was as follows [22]: LecT-Hepa =
log10[AOL/DSA] × 8.6 – [MAL/DSA].
Zou et al. Clinical Proteomics 2014, 11:44 Page 9 of 10
http://www.clinicalproteomicsjournal.com/content/11/1/44Statistical analysis
Statistical calculations were conducted with Microsoft
Office Excel and SPSS version 16.0 statistical package
(SPSS, Chicago, IL, USA). Categorical data were ana-
lyzed using χ2 test and continuous variables were com-
pared with the Student’s t test or Mann–Whitney U test.
In addition to assessing the predictive ability of vari-
ous markers to differentiate SVR from non-SVR patients,
ROC curve analysis was performed. Diagnostic accuracy
was expressed as the diagnostic specificity, sensitivity, PPV,
NPV, and AUC. The cutoff values were obtained from
Youden’s index [48]. A p value <0.05 in all cases was con-
sidered statistically significant.Additional files
Additional file 1: Figure S1. Trend analysis of the levels of LecT-Hepa,
FIB-4, and APRI during 48 weeks of IFN treatment in 45 CHC patients.
Additional file 2: Figure S2. Clinical information for SVR and non-SVR
patients at 0–48 weeks.
Additional file 3: Figure S3. Relation of the levels of LecT-Hepa, FIB-4,
and APRI with HCV genotype. We compared the levels of LecT-Hepa,
FIB-4, and APRI during 48 weeks of IFN therapy in patients with different
HCV genotype (dot: HCV genotype 1b; circle: HCV genotype 2a).Abbreviations
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ELF: Enhanced liver fibrosis; AGP: α1-acid glycoprotein; DSA: Datura
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